[{"address1": "700 Quince Orchard Road", "city": "Gaithersburg", "state": "MD", "zip": "20878", "country": "United States", "phone": "240 268 2000", "website": "https://www.novavax.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.", "fullTimeEmployees": 1543, "companyOfficers": [{"maxAge": 1, "name": "Mr. John Charles Jacobs M.B.A.", "age": 56, "title": "President, CEO & Director", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 1329651, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John Joseph Trizzino B.S., M.B.A.", "age": 63, "title": "President & COO", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 670550, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James Patrick Kelly C.F.A.", "age": 57, "title": "Executive VP, CFO & Treasurer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 716175, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark  Casey", "age": 60, "title": "Executive VP, Chief Legal Officer & Corporate Secretary", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 137357, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Richard P. Crowley", "age": 66, "title": "Executive VP & COO", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robert  Walker M.D.", "title": "Senior VP, Chief Medical Officer and Interim Head of R&D", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Troy  Morgan Esq., J.D.", "age": 52, "title": "Senior VP, Deputy General Counsel & Chief Compliance Officer", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Erika S. Trahan", "title": "Associate Director of Investor & Public Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ian J. Watkins", "age": 60, "title": "Executive VP & Chief Human Resources Officer", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Silvia  Taylor M.B.A.", "title": "Executive VP and Chief Corporate Affairs & Advocacy Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 5, "compensationRisk": 7, "shareHolderRightsRisk": 5, "overallRisk": 6, "governanceEpochDate": 1730419200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 9.44, "open": 9.12, "dayLow": 8.425, "dayHigh": 9.27, "regularMarketPreviousClose": 9.44, "regularMarketOpen": 9.12, "regularMarketDayLow": 8.425, "regularMarketDayHigh": 9.27, "beta": 2.033, "forwardPE": -56.0, "volume": 6365050, "regularMarketVolume": 6365050, "averageVolume": 6105233, "averageVolume10days": 4139870, "averageDailyVolume10Day": 4139870, "bid": 8.89, "ask": 9.03, "bidSize": 4200, "askSize": 4200, "marketCap": 1434442240, "fiftyTwoWeekLow": 3.53, "fiftyTwoWeekHigh": 23.86, "priceToSalesTrailing12Months": 1.4523541, "fiftyDayAverage": 11.8104, "twoHundredDayAverage": 9.8546, "currency": "USD", "enterpriseValue": 648382016, "profitMargins": -0.29801, "floatShares": 143301417, "sharesOutstanding": 160094000, "sharesShort": 35718187, "sharesShortPriorMonth": 33531081, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.22309999, "heldPercentInsiders": 0.0438, "heldPercentInstitutions": 0.55118, "shortRatio": 5.59, "shortPercentOfFloat": 0.2783, "bookValue": -2.7, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "earningsQuarterlyGrowth": 1.799, "netIncomeToCommon": -294334016, "trailingEps": -2.48, "forwardEps": -0.16, "pegRatio": -0.31, "lastSplitFactor": "1:20", "lastSplitDate": 1557446400, "enterpriseToRevenue": 0.656, "enterpriseToEbitda": -2.692, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "NVAX", "underlyingSymbol": "NVAX", "shortName": "Novavax, Inc.", "longName": "Novavax, Inc.", "firstTradeDateEpochUtc": 818173800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "cdb3cddb-5091-3918-86d6-9b4894e61c6c", "gmtOffSetMilliseconds": -18000000, "currentPrice": 8.96, "targetHighPrice": 26.0, "targetLowPrice": 14.0, "targetMeanPrice": 19.6, "targetMedianPrice": 19.0, "recommendationMean": 2.5, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 1049593984, "totalCashPerShare": 6.556, "ebitda": -240839008, "totalDebt": 263536992, "quickRatio": 0.934, "currentRatio": 1.039, "totalRevenue": 987667008, "revenuePerShare": 7.659, "returnOnAssets": -0.10212, "freeCashflow": -97843376, "operatingCashflow": 14278000, "earningsGrowth": 0.709, "revenueGrowth": -0.021, "grossMargins": 0.16174999, "ebitdaMargins": -0.24385001, "operatingMargins": 0.39014, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-11-07"}]